All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Visual Abstract | Risankizumab vs apremilast for plaque psoriasis: Results from IMMpulse
By Ella Dixon
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing data from the phase IV IMMpulse trial, which compared risankizumab to apremilast in patients with chronic plaque psoriasis up to 52 weeks.
Treatment with risankizumab resulted in more patients achieving a 90% improvement in Psoriasis Area and Severity Index (PASI 90) at Week 16 compared with those treated with apremilast. In addition, patients who were PASI 75 non-responders and switched to risankizumab from apremilast at Week 16 achieved a greater rate of PASI 90 at Week 52 compared with patients who remained on apremilast.
- Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adult patients 2 with moderate plaque psoriasis eligible for systemic therapy: results from a 3 randomised, open-label, assessor-blinded phase IV (IMMpulse) study. Br J Dermatol. 2023. Online ahead of print. DOI: 1093/bjd/ljad252
Your opinion matters
6 votes - 85 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox